Other Clinical Trial - A Study to Investigate the Efficacy & Safety of

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The primary objective of the study is to observe efficacy in terms of progression-free survival rate at 6 months in eribulin-treated breast cancer participants retrospectively.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details

NCT number	NCT03437083
Study type	Observational
Source	Eisai Inc.
Contact
Status	Completed
Phase
Start date	January 25, 2018
Completion date	June 30, 2018

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05860465` - Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer	Phase 2/Phase 3
	Active, not recruiting	`NCT03781063` - Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 2
	Recruiting	`NCT05054751` - GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Phase 3
	Completed	`NCT03027245` - Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
	Not yet recruiting	`NCT05172518` - Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer	Phase 3
	Recruiting	`NCT05430399` - Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer	Phase 3
	Terminated	`NCT00634088` - Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Phase 1
	Not yet recruiting	`NCT05403333` - Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer	Phase 2
	Recruiting	`NCT05296798` - A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)	Phase 3
	Recruiting	`NCT05744687` - Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer	Phase 2/Phase 3
	Active, not recruiting	`NCT06439771` - A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	Phase 2
	Withdrawn	`NCT05212701` - To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	Phase 2